Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
December 16, 2022 08:10 ET
|
Amicus Therapeutics, Inc.
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with...
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
November 15, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New...
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
November 07, 2022 12:20 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
November 07, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
Year-to-Date 2022 Reported Revenue Growth of 8% (16% at CER) On-Track to Deliver Full-Year 2022 Double-Digit Revenue Growth of 15-20% at CER Advancing Launch Preparation for AT-GAA in Pompe Disease...
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
October 28, 2022 16:01 ET
|
Amicus Therapeutics, Inc.
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date Company is Now Actively Engaged...
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
October 27, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at...
Amicus Therapeutics Announces Participation at World Muscle Society 2022
October 11, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced four poster presentations highlighting its development program for Pompe disease will be included...
Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting
September 21, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be...
Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 08, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global...
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
August 04, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7% On-Track to Deliver Full-Year Double-Digit Revenue Growth of...